AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2020
Jan 3, 2020
30591_dirs_2020-01-03_1fec2eed-05bb-460e-adac-4fc89f355d23.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2020-01-02
Reporting Person: Monia Brett P (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-01-02 | Common Stock | S | 173 | $60.25 | Disposed | 16285 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-01-02 | Employee Stock Option (right to buy) | $60.89 | A | 158659 | Acquired | 2027-01-01 | Common Stock (158659) | Direct |
Footnotes
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019.
F2: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.